Cognition Therapeutics announces positive Phase 2 SEQUEL topline results for CT1812 in Alzheimer's

COGNITION THERAPEUTICS INC

Phase 2 SEQUEL study met primary safety and tolerability endpoints; CT1812 well-tolerated with no treatment-related SAEs.
CT1812 showed numerical reduction in relative theta power vs placebo on qEEG, indicating positive impact on brain activity.
Nominal statistical significance achieved for reduced relative theta in central brain region and for AECc brain connectivity measure.
Study involved 16 adults with mild-to-moderate Alzheimer's; full results to be presented at upcoming medical meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.